MedTrace Logo

A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers

NCT04839042 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2025-08-21

No results posted yet for this study

Summary

This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the intramuscular (IM), intranasal (IN) or inhaled (IH) route in healthy volunteers.

Conditions

  • Covid19

Interventions

BIOLOGICAL

SC-Ad6-1

SC-Ad6-1, I.M., single or multiple-dose

BIOLOGICAL

SC-Ad6-1

SC-Ad6-1, I.N., single or multiple-dose

BIOLOGICAL

SC-Ad6-1

SC-Ad6-1, I.H., single or multiple-dose

Sponsors & Collaborators

  • Moat Biotechnology Corporation

    lead INDUSTRY

Principal Investigators

  • Russell Rother, Ph.D. · Moat Biotechnology Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-28
Primary Completion
2025-03-04
Completion
2025-03-04
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04839042 on ClinicalTrials.gov